STOCK TITAN
  1. Home
  2. News
  3. CLPT

ClearPoint Neuro, Inc. - CLPT STOCK NEWS

Welcome to our dedicated page for ClearPoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on ClearPoint Neuro stock.

ClearPoint Neuro, Inc. (symbol: CLPT) is a leading medical device company based in the United States, specializing in the development and commercialization of innovative platforms designed for performing minimally invasive surgical procedures in both the brain and heart, utilizing magnetic resonance imaging (MRI) guidance. Since its inception in 1998, ClearPoint Neuro has been at the forefront of interventional MRI research and product development.

The company's flagship product, the ClearPoint® System, is currently being used in the United States for minimally invasive brain surgeries. This system allows for precision and real-time visualization during complex neurosurgical procedures, significantly improving patient outcomes. The ClearTrace® System, still under development, aims to bring similar advancements to cardiac surgeries, offering minimally invasive solutions for heart procedures.

ClearPoint Neuro's product portfolio includes the ClearPoint System, ClearPoint Services, and ClearPoint Therapeutic Solutions. Their latest innovation, the Prism Neuro Laser Therapy System, received FDA clearance and has been integrated with the company's SmartFrame Array® 1.2 software, enhancing the practicality and efficiency of neuro laser therapies. This integration allows for combined biopsy and laser therapy procedures to be performed in a single setting, reducing setup times and improving procedural accuracy.

Financially, ClearPoint Neuro has shown robust growth. In the fourth quarter of 2023, the company reported a record revenue of $6.8 million, marking a 30% increase. Their strategic partnerships, including those with clinical and pharmaceutical firms, further bolster their financial stability and market reach. The recent equity offering of approximately $15 million has solidified their balance sheet, reinforcing investor confidence in their continued growth and innovation.

ClearPoint Neuro is also deeply involved in advancing gene and cell therapy. Their SmartFlow® Cannula is a key device used globally for delivering approved gene therapies directly to the brain. This device has been instrumental in numerous clinical trials, including those for treating AADC deficiency and Frontotemporal Dementia (FTD).

Overall, ClearPoint Neuro remains committed to driving innovation in the medical field, with a strong focus on improving surgical outcomes through advanced imaging and precise navigation technologies. For more information, visit their website at www.clearpointneuro.com.

News

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announces the pricing of its underwritten public offering of 2,307,694 shares of common stock at $6.50 per share, with an option for additional shares. The offering aims to raise funds for general corporate purposes, including research, acquisitions, or debt repayment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.23%
Tags
offering
-
News

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announced a proposed underwritten public offering of its common stock, with the potential for additional shares to be offered. The offering is subject to market conditions, with Lake Street Capital Markets, LLC acting as the book-running manager. The SEC declared the shelf registration statement effective in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.23%
Tags
offering
-
News

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Rhea-AI Summary
ClearPoint Neuro, Inc. announces FDA Clearance and first-in-human cases using ClearPoint 2.2 Software with Maestro Brain Modeling. A key validation study for ClearPoint Maestro® Brain Model published in NeuroImage. The company aims to offer precise navigation for brain and spine procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
clinical trial
News

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announced the successful installation and completion of an initial procedure with the ClearPoint Prism Neuro Laser Therapy System and the ClearPoint Neuro Navigation System at Kaleida Health in Buffalo, New York. Dr. Jonathan Riley and team performed the procedure, marking the first successful case with combined MRI targeting and laser ablation solutions. The company looks forward to expanding into full market release later this year. The Prism laser is currently in limited market release at select academic medical centers across the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
News

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) has received European Medical Device Regulation (EU MDR) clearance for the manual SmartTwist® MR Hand Drill and SmartTip® MR Drill Kit. The company also obtained updated certification from its Notified Body for shipment of products manufactured at its new Carlsbad, California facility to Europe. The EU MDR places greater emphasis on safety measures, risk management, post-market surveillance, and data collection of medical devices for companies seeking European market access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) has received 510(k) clearance for its SmartFrame OR™ Stereotactic System, marking a strategic shift into the operating room. The system, composed of the SmartFrame OR and ClearPointer™ Optical Navigation Wand, aims to provide precise navigation for neurological procedures without the need for MRI, expanding the company's reach to more hospitals and patients. Limited market release is set for the first half of 2024, with a full market release planned for the second half.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
clinical trial
News

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announced preliminary unaudited financial results for Q4 2023 and full year 2023. Q4 highlights include a 32% year-over-year increase in revenue to $6.8 million, a 76% increase in biologics and drug delivery revenue to $4.1 million, and a cash burn of $1.2 million. Full year 2023 saw a record revenue of $24 million, a 17% increase, and a 49% increase in biologics and drug delivery revenue to $13.6 million. The company estimates 2024 revenue to be between $28 million and $32 million, with several new product introductions planned. The CEO expressed optimism about the company's performance and future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.91%
Tags
none
-
News

ClearPoint Neuro Reports Third Quarter 2023 Results

Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) reports Q3 revenue of $5.8M, a 12% YoY increase, with biologics and drug delivery revenue growing 55% to $3.5M. Operational cash burn at $1.8M, the lowest since 2020. The company forecasts 2023 revenue between $23.0M and $25.0M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.71%
Tags
earnings
-
News

ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

Rhea-AI Summary
ClearPoint Neuro, Inc. will release its 2023 third quarter financial results on November 9. Investors and analysts can participate in the live broadcast review or access the replay afterwards. The Company's Investor website will also have an online archive of the broadcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
earnings
News

ClearPoint Neuro Reports Second Quarter 2023 Results

Rhea-AI Summary
ClearPoint Neuro, Inc. reports a record quarterly revenue of $6.0 million, a 14% YoY increase. Biologics and drug delivery revenue increased by 40% YoY to $3.4 million. The company reaffirms its 2023 revenue outlook of $25.0 to $27.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
earnings

FAQ

What is the current stock price of ClearPoint Neuro (CLPT)?

The current stock price of ClearPoint Neuro (CLPT) is $15.545 as of December 20, 2024.

What is the market cap of ClearPoint Neuro (CLPT)?

The market cap of ClearPoint Neuro (CLPT) is approximately 412.6M.

What does ClearPoint Neuro, Inc. do?

ClearPoint Neuro, Inc. develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart using MRI guidance.

What is the ClearPoint® System?

The ClearPoint® System is a platform used in the United States for minimally invasive brain surgeries, allowing for precision and real-time visualization during procedures.

Is the ClearTrace® System available?

The ClearTrace® System is currently under development and aims to bring minimally invasive solutions to cardiac surgeries.

What recent advancements has ClearPoint Neuro made?

ClearPoint Neuro has integrated its Prism Neuro Laser Therapy System with the SmartFrame Array® 1.2 software, enhancing the efficiency and accuracy of neuro laser therapies.

What financial achievements did ClearPoint Neuro report in the fourth quarter of 2023?

ClearPoint Neuro reported a record revenue of $6.8 million in the fourth quarter of 2023, marking a 30% increase.

What is the SmartFlow® Cannula used for?

The SmartFlow® Cannula is used for delivering approved gene therapies directly to the brain and is utilized in various clinical trials and research studies.

How does ClearPoint Neuro contribute to gene and cell therapy?

ClearPoint Neuro provides precise navigation and delivery solutions for gene and cell therapy, partnering with pharmaceutical and biotech companies for preclinical and clinical trials.

Where can I find more information about ClearPoint Neuro?

You can find more information about ClearPoint Neuro on their website at www.clearpointneuro.com.

How has ClearPoint Neuro's financial status improved recently?

The company completed an equity offering of approximately $15 million, which solidified their balance sheet and allowed them to retire outstanding debt.

What is the significance of the Prism Neuro Laser Therapy System?

The Prism Neuro Laser Therapy System provides a more efficient and precise solution for neuro laser therapies, recently achieving FDA clearance and limited market release in select academic centers.

Stock CLPT logo
ClearPoint Neuro, Inc.

Nasdaq:CLPT

CLPT Rankings

#3254 Ranked by Market Cap
N/A Ranked by Dividends

CLPT Stock Data

412.64M
25.42M
7.83%
30.52%
2.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SOLANA BEACH